PACB•benzinga•
PacBio Says In Response To Ongoing Market Uncertainty, PacBio Is Executing A Plan To Reduce Both Headcount Across All Functions And Non-Headcount Related Expenses To Lower Its Annualized Non-GAAP Operating Expense Run-Rate By $45M-$50M
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 9, 2025 by benzinga